Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Raises $56.1M in Public Offering

NEW YORK (GenomeWeb News) – Fluidigm today said it has closed on its public offering of 4,209,000 shares of its common stock and raised $56.1 million in net proceeds.

The South San Francisco, Calif.-based firm announced the offering last week and priced its shares at $14.25. It plans to use proceeds for R&D, commercialization efforts, working capital, and other general corporate purposes.

Piper Jaffray and Cowen and Co, acted as joint book-running managers on the offering, while Leerink Swann, Oppenheimer, and Cantor Fitzgerald were co-managers. The underwriters exercised their over-allotment option in full to purchase 549,000 shares, Fluidigm said.

The company went public in February 2011.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.